Quanterix (NASDAQ:QTRX) Raised to “Hold” at Wall Street Zen

Quanterix (NASDAQ:QTRX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

QTRX has been the topic of several other research reports. Canaccord Genuity Group lifted their price target on shares of Quanterix from $5.00 to $8.00 and gave the company a “hold” rating in a report on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quanterix in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $11.33.

Quanterix Stock Down 0.5%

Shares of Quanterix stock opened at $6.33 on Monday. The company’s fifty day simple moving average is $6.35 and its two-hundred day simple moving average is $5.82. Quanterix has a 12-month low of $4.05 and a 12-month high of $12.41. The firm has a market cap of $295.67 million, a PE ratio of -2.72 and a beta of 1.01.

Quanterix (NASDAQ:QTRX) last posted its earnings results on Monday, November 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.13). The business had revenue of $40.23 million during the quarter, compared to the consensus estimate of $37.85 million. Quanterix had a negative return on equity of 21.34% and a negative net margin of 73.47%. As a group, sell-side analysts expect that Quanterix will post -0.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its holdings in Quanterix by 9.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 292,805 shares of the company’s stock worth $1,906,000 after acquiring an additional 26,190 shares in the last quarter. Invesco Ltd. boosted its stake in Quanterix by 61.0% in the 1st quarter. Invesco Ltd. now owns 54,194 shares of the company’s stock worth $353,000 after purchasing an additional 20,540 shares in the last quarter. American Century Companies Inc. grew its position in Quanterix by 9.9% during the 1st quarter. American Century Companies Inc. now owns 79,130 shares of the company’s stock valued at $515,000 after purchasing an additional 7,138 shares during the last quarter. Hsbc Holdings PLC increased its stake in Quanterix by 60.7% during the 1st quarter. Hsbc Holdings PLC now owns 31,133 shares of the company’s stock valued at $200,000 after purchasing an additional 11,762 shares in the last quarter. Finally, State of Wyoming bought a new stake in Quanterix during the 1st quarter valued at about $47,000. Institutional investors own 86.48% of the company’s stock.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.